Abstract: A transdermal, biodegradable microneedle system and method for treating pain in a patient. The transdermal easy-to-use biodegradable microneedle system can be fully embedded into the skin to perform a sustained and nearly zero-order release kinetics of therapeutics over a long period of time (at least 30 days) for the treatment of pain.

Abstract: The present application discloses a number of inventions directed to method(s), apparatus and/or networks and systems adapted to track time varying channels, adapted to synchronize packets arriving at a receiver, adapted to correlate a received signal, adapted to manage digital resources, adapted to receive a signal and/or adapted to enable communication in a wireless packet based communications network.

Abstract: The present application discloses a number of inventions directed to method(s), apparatus and/or networks and systems adapted to track time varying channels, adapted to synchronise packets arriving at a receiver, adapted to correlate a received signal, adapted to manage digital resources, adapted to receive a signal and/or adapted to enable communication in a wireless packet based communications network.

Abstract: The present application discloses a number of inventions directed to method(s), apparatus and/or networks and systems adapted to track time varying channels, adapted to synchronize packets arriving at a receiver, adapted to correlate a received signal, adapted to manage digital resources, adapted to receive a signal and/or adapted to enable communication in a wireless packet based communications network.

Abstract: Pro-drug forms of linear polyamine-bridged platinum compounds and methods for their production and use are provided. The polyamine-bridge portion of the compounds is based on spermine or spermidine, and the central amines of the polyamine-bridge are chemically bonded to labile blocking groups. The presence of the blocking groups serves to minimize the toxicity of the Pt compounds upon administration. Selective removal of the blocking groups and release of the active, unblocked species occurs upon exposure to suitable environmental conditions.

Abstract: Trans-platinum compounds comprising carboxylato groups are disclosed, with anti-cancer usefulness. The carboxylato groups participate in solubilizing trans-platinum compounds to which they are attached.

Abstract: A parallel concatenated coder (20) outputs a sequence of data sets in which earlier data sets contain data bits (d) and non-interleaved parity bits (p) without interleaved parity bits (q), while later data sets include the interleaved parity bits (q). Each data set is modulated as one symbol. The output format partially overcomes the delay incurred by interleaving the parity bits (q), with a substantially even distribution of data and parity bits in the sequence of data sets. The delay may be reduced further by interleaving with an index constraint.

Abstract: Pro-drug forms of linear polyamine-bridged platinum compounds and methods for their production and use are provided. The polyamine-bridge portion of the compounds is based on spermine or spermidine, and the central amines of the polyamine-bridge are chemically bonded to labile blocking groups. The presence of the blocking groups serves to minimize the toxicity of the Pt compounds upon administration. Selective removal of the blocking groups and release of the active, unblocked species occurs upon exposure to suitable environmental conditions.

Abstract: The invention provides a method for enhancing the water solubility of cytotoxic trans-platinum complexes. The present invention also provides a method for killing tumor cells, and a method for the treatment of tumors by the administration of a cytotoxic platinum coordination complex of the general formula SP4-2-[PtX(L)(L′)(B)]+.

Abstract: The present invention relates to tetra- and penta-nuclear platinum complexes with antitumor activity, to a method for preparing them and to pharmaceutical compositions containing them.

Abstract: The invention provides an improved method for the delivery and stabilization of antisense oligodeoxynucleotides (ODNs) to cells. The unmodified ODNs are complexed to a polynuclear platinum compound or to a structural derivative thereof. Complexation neutralizes the charge of the ODN and makes possible its passage into the cell, without the addition of other transfection agents. The invention may be used in the treatment any disease which is amenable to treatment by antisense ODNs. In addition, the invention provides a new method specifically for the treatment of cancer.

Abstract: The present invention relates to treatment of viral infections, such as HIV, with a new class of anti-viral platinum coordination compounds having the general structural formula [PtXA.sub.m B.sub.3-m ] where X is an anionic ligand, A is an acyclic, nitrogen containing monodentate ligand such as amines, ammines, and quinolines, and B is nucleobase.

Abstract: The present invention relates to trinuclear cationic platinum complexes with alkylene diamine groups connecting the three platinum moieties. The invention also relates to the antitumor activity of these complexes as well as the processes for the preparation thereof and pharmaceutical compositions containing them.

Abstract: A bis(platinum) complex having the structure: ##STR1## wherein X, Y, Z, X', Y', and Z' are the same or different ligands and are halide, sulphate, phosphate, nitrate, carboxylate, substituted carboxylate, dicarboxylate, substituted dicarboxylate primary or secondary amine, sulfoxide, phosphine, pyridine-type nitrogen and the like; preferably, there is at least one Pt-anion bond on each Pt molecule; and A is a diamine or polyamine.Complexes of trans geometry ?PtX.sub.2 (L)(L')! where at least L is a planar ligand such as pyridine but preferably quinoline and L' may be amine, sulfoxide or substituted sulfoxide and X is a chloride, nitrate or carboxylate.A process for obtaining bis(platinum) complexes where the two platinum coordination spheres may contain different ligands in each sphere and where the geometry of each platinum coordination sphere may be the same or different.

Abstract: Compounds of general formula (I) wherein: n is an integer from 2 to 7 included; Z.sup.-m is an anion selected from chloride, bromide, iodide, nitrate, sulfate; m is the integer 1 or 2. Said compounds have antitumour activity.

Abstract: Novel trans-platinum IV complexes which contain heterocycle ligands such as quinoline or isoquinoline, anionic ligands such as halide or sulfate, and which optionally may contain ammonia, or a primary or secondary amine are provided. These complexes have application as pharmaceuticals, in particular as anti-tumor agents.

Abstract: Novel bis(platinum) (IV) complexes coupled via diamine bridging agents are taught as well as methods for their preparation. These complexes are to be used as pharmaceutical agents, e.g., for the treatment of cancer and parasitic diseases.

Abstract: Novel tri(platinum) complexes containing three platinum coordination spheres coupled via diamine or triamine bridging agents are taught as well as methods for their preparation. These complexes are to be used as pharmaceutical agents, e.g., for the treatment of cancer and parasitic diseases.

Abstract: A bis(platinum) complex having the structure: ##STR1## wherein X, Y, Z, X', Y', and Z' are the same or different ligands and are halide, sulphate, phosphate, nitrate, carboxylate, substituted carboxylate, dicarboxylate, substituted dicarboxylate primary or secondary amine, sulfoxide, phosphine, pyridine-type nitrogen and the like; preferably, there is at least one Pt-anion bond on each Pt molecule; and A is a diamine or polyamine.Complexes of trans geometry [PtX.sub.2 (L)(L')] where at least L is a planar ligand such as pyridine but preferably quinoline and L' may be amine, sulfoxide or substituted sulfoxide and X is a chloride, nitrate or carboxylate.A process for obtaining bis(platinum) complexes where the two platinum coordination spheres may contain different ligands in each sphere and where the geometry of each platinum coordination sphere may be the same or different.

Abstract: A bis-platinum complex having the structure: ##STR1## wherein X and Y are the same or different ligands and are halide, sulphate, phosphate, nitrate, carboxylate, substituted carboxylate or dicarboxylate. B and C are the same or different and are primary or secondary amines, or pyridine type nitrogens. A is a diamine or polyamine wherein the primary amine N atoms are coordinated to the Pt atom such that platinum is present as Pt.sup.2+. The complexes are useful in the inhibition of tumors.